Assessing Effects of Sublingual BHV-0223 and Oral Riluzole on Liver Function Test Parameters

Authors: Howell BA
Conference: SOT
Keywords: drug development, hepatotoxicity, liver function, liver safety, oral riluzole, pharmaceutical risk assessment
Software: DILIsym®
Division: Quantitative Systems Pharmacology (QSP)

DILIsym is a mechanistic, mathematical model that has been constructed to support pharmaceutical risk assessment and decision making
– Intersection of compound distribution and metabolism (PBPK), hepatotoxicity mechanisms, and patient variability

  •  DILIsym has been applied to support decisions related to compound DILI risk
    throughout the drug development pipeline
  • DILIsym was used to compare the possible liver safety effects of two different
    formulations of riluzole, used to slow the progression of ALS

By Brett A Howell

Society of Toxicology 58th Annual Meeting and ToxExpo, March 10-14, 2019, Baltimore, MD